Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells.
Van Herpen CM, Huijbens R, Looman M, De Vries J, Marres H, Van De Ven J, Hermsen R, Adema GJ, De Mulder PH. Van Herpen CM, et al. Among authors: van de ven j. Clin Cancer Res. 2003 Aug 1;9(8):2950-6. Clin Cancer Res. 2003. PMID: 12912941 Clinical Trial.
Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes.
van Herpen CM, Looman M, Zonneveld M, Scharenborg N, de Wilde PC, van de Locht L, Merkx MA, Adema GJ, de Mulder PH. van Herpen CM, et al. Among authors: van de locht l. Clin Cancer Res. 2004 Apr 15;10(8):2626-35. doi: 10.1158/1078-0432.ccr-03-0304. Clin Cancer Res. 2004. PMID: 15102664 Clinical Trial.
Current treatment of renal cell carcinoma.
De Mulder PH, van Herpen CM, Mulders PA. De Mulder PH, et al. Among authors: van herpen cm. Ann Oncol. 2004;15 Suppl 4:iv319-28. doi: 10.1093/annonc/mdh946. Ann Oncol. 2004. PMID: 15477330 Free article. Review. No abstract available.
Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
van Herpen CM, van der Laak JA, de Vries IJ, van Krieken JH, de Wilde PC, Balvers MG, Adema GJ, De Mulder PH. van Herpen CM, et al. Among authors: van der laak ja, van krieken jh. Clin Cancer Res. 2005 Mar 1;11(5):1899-909. doi: 10.1158/1078-0432.CCR-04-1524. Clin Cancer Res. 2005. PMID: 15756016 Clinical Trial.
Interleukin-12 has no effect on vascular density, perfusion, hypoxia and proliferation of an implanted human squamous cell carcinoma xenograft tumour despite up-regulation of ICAM-1.
van Herpen CM, Bussink J, van der Kogel AJ, Peeters WJ, van der Voort R, van Schijndel A, de Wilde PC, Adema GJ, de Mulder PH. van Herpen CM, et al. Among authors: van der kogel aj, van der voort r, van schijndel a. Anticancer Res. 2005 Mar-Apr;25(2A):1015-21. Anticancer Res. 2005. PMID: 15868941 Free article.
Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation.
van Herpen CM, van der Voort R, van der Laak JA, Klasen IS, de Graaf AO, van Kempen LC, de Vries IJ, Boer TD, Dolstra H, Torensma R, van Krieken JH, Adema GJ, De Mulder PH. van Herpen CM, et al. Among authors: van kempen lc, van der laak ja, van der voort r, van krieken jh. Int J Cancer. 2008 Nov 15;123(10):2354-61. doi: 10.1002/ijc.23756. Int J Cancer. 2008. PMID: 18729197 Clinical Trial.
258 results